About SynapDx
SynapDx is a company based in Southborough (United States) founded in 2010. It operates as a D2C and B2C. SynapDx has raised $32.75 million across 5 funding rounds from investors including LabCorp, Flare Capital Partners and North Bridge Venture Partners. SynapDx offers products and services including Spectros 280 IU, Genotropin 36 IU, Semaglutide 5 mg, and Zptropin 160 IU. SynapDx operates in a competitive market with competitors including Linus Biotechnology, Lineagen, MARAbio, SensOmics and Pediatric Bioscience, among others.
- Headquarter Southborough, United States
-
Sectors
HealthcareConsumer
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Thesah
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$32.75 M (USD)
in 5 rounds
-
Latest Funding Round
$15.4 M (USD), Series C
Jul 24, 2013
-
Investors
LabCorp
& 6 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SynapDx
SynapDx offers a comprehensive portfolio of products and services, including Spectros 280 IU, Genotropin 36 IU, Semaglutide 5 mg, and Zptropin 160 IU.
Provides growth hormone for energy and muscle enhancement.
Supports hormone therapy for recovery and performance.
Assists in fat reduction and metabolic health improvement.
Offers hormone for anti-aging and vitality benefits.
Funding Insights of SynapDx
SynapDx has successfully raised a total of $32.75M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $15.4 million completed in July 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SynapDx
SynapDx has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include LabCorp, Flare Capital Partners and North Bridge Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage tech startups are funded by this venture capital firm.
|
Locked | Locked | Locked | |
|
US focused seed to growth stage VC firm
|
Locked | Locked | Locked | |
|
Investment and transformation services for entrepreneurs in technology and finance sectors.
|
Locked | Locked | Locked |
Investor details for SynapDx
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SynapDx
Investment portfolio details for SynapDx
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SynapDx
Detailed financials for SynapDx
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synapdx Comparisons
Peer comparison for SynapDx
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SynapDx
SynapDx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Linus Biotechnology, Lineagen, MARAbio, SensOmics and Pediatric Bioscience, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of diagnostic tests for central nervous system and gastrointestinal disorders
|
|
| Locked | Locked | Locked |
Sequencing-based diagnostic tests and services for autism are provided.
|
|
| Locked | Locked | Locked |
A blood test for maternal autoantibody-related autism is developed.
|
|
| Locked | Locked | Locked |
Precision medicine for children's health is provided through genomic integration.
|
|
| Locked | Locked | Locked |
Provides blood biomarker-based diagnostics for autism spectrum disorders.
|
Detailed competitors of SynapDx
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synapdx
Complete news archive for SynapDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SynapDx
SynapDx was founded in 2010.
SynapDx is headquartered in Southborough, United States. It is registered at Southborough, Massachusetts, United States.
SynapDx is a funded company, having raised a total of $32.75M across 5 funding rounds to date.
SynapDX operates as an online retailer specializing in human growth hormone (HGH) products, including injections and pens, to enhance energy, muscle growth, and recovery. It provides lab-tested items with fast delivery options, targeting adults focused on fitness and anti-aging. The platform emphasizes safe purchasing, verified brands, and customer support, while advising medical consultation for use.
SynapDx's top competitors include Linus Biotechnology, MARAbio and Lineagen.
SynapDx offers Spectros 280 IU, Genotropin 36 IU, Semaglutide 5 mg, and Zptropin 160 IU.
SynapDx has 7 investors. Key investors include LabCorp, Flare Capital Partners, North Bridge Venture Partners, General Catalyst, and Google Ventures.